With the advent of high-throughput screening for drug candidates in CMT,20 preclinical evidence of benefit in immune modulation,21 and a successful gene replacement therapy in a mouse model of CMTX1,22 one anticipates therapeutic clinical trials in CMTX1. Here, GJB1 is linked to Charcot-Marie-Tooth disease.